BRAF and colorectal carcinoma: The BRAFV600E mutation CRC PDOs showed great reduced cell viability instead of promoting cell apoptosis after the treatment of vemurafenib (a BRAF inhibitor) when compared with those of the wide type BRAF CRC PDOs, which may explain the ineffectiveness of BRAF inhibitors for mCRC patients in clinic [53].